Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis
- Published on 07/05/2024
- Reading time: 4 min.
S. Chandrashekara *
Department of Clinical Immunology and Rheumatology, ChanRe Rheumatology and Immunology Center and Research, Bengaluru, India
CONTACT S. Chandrashekara mailto:chandrashekara_s@yahoo.com Department of Clinical Immunology and Rheumatology, ChanRe Rheumatology and Immunology Center and Research, 20th Main Rd, near Rajajinagar, West of Chord Road 2nd Stage, Rajajinagar, Bengaluru, Karnataka 560010, India
Abstract
Introduction In the realm of autoimmune rheumatic diseases, understanding JAK inhibitors (JAKi) nuances is vital. Baricitinib, tofacitinib, upaacitinib, filgotinib, and peficitinib exhibit subtle yet impactful pharmacokinetic (PK) and pharmacodynamic (PD) variations.
Areas covered This narrative review critically assesses PK and PD distinctions among globally approved JAKi for rheumatoid arthritis, which primarily guide clinical decisions in autoimmune...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Rheumatology
Receive our newsletter to stay up to date with the latest news in Rheumatology